Literature DB >> 30109642

Cannabinoid-Based Therapies and Brain Development: Potential Harmful Effect of Early Modulation of the Endocannabinoid System.

Patrícia Schonhofen1,2,3, Ivi Juliana Bristot1,2,3, José Alexandre Crippa3,4, Jaime Eduardo Cecílio Hallak3,4, Antônio Waldo Zuardi3,4, Richard B Parsons5, Fábio Klamt6,7,8.   

Abstract

The endocannabinoid retrograde signaling pathway is widely expressed in the central nervous system, where it plays major roles in regulating synaptic plasticity (excitatory and inhibitory) through long-term potentiation and long-term depression. The endocannabinoid system (ECS) components-cannabinoid receptors, endocannabinoids and synthesis/degradation enzymes-are expressed and are functional from early developmental stages and throughout adolescent cortical development, regulating progenitor cell fate, neural differentiation, migration and survival. This may potentially confer increased vulnerability to adverse outcomes from early cannabinoid exposure. Cannabidiol (CBD) is one of the most studied exogenous cannabinoids, and CBD-enriched Cannabis extracts have been widely (and successfully) used as adjuvants to treat children with refractory epilepsy, and there is even a Food and Drug Administration (FDA)-approved drug with purified CBD derived from Cannabis. However, there is insufficient information on possible long-term changes in the central nervous system caused by cannabinoid treatments during early childhood. Like the majority of cannabinoids, CBD is able to exert its effects directly and indirectly through the ECS, which can perturb the regulatory processes mediated by this system. In addition, CBD has a large number of non-endocannabinoid targets, which can explain CBD's effects. Here, we review the current knowledge about CBD-based therapies-pure and CBD-enriched Cannabis extracts-in studies with pediatric patients, their side effects, and their mechanisms of action regarding the central nervous system and neurodevelopment aspects. Since Cannabis extracts contain Δ9-tetrahydrocannabinol (Δ9-THC), we consider that pure CBD is possibly safer for young patients. Nevertheless, CBD, as well as other natural and/or synthetic cannabinoids, should be studied in more detail as a therapeutic alternative to CBD-enriched Cannabis extracts for young patients.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30109642     DOI: 10.1007/s40263-018-0550-4

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  80 in total

1.  Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.

Authors:  Orrin Devinsky; Eric Marsh; Daniel Friedman; Elizabeth Thiele; Linda Laux; Joseph Sullivan; Ian Miller; Robert Flamini; Angus Wilfong; Francis Filloux; Matthew Wong; Nicole Tilton; Patricia Bruno; Judith Bluvstein; Julie Hedlund; Rebecca Kamens; Jane Maclean; Srishti Nangia; Nilika Shah Singhal; Carey A Wilson; Anup Patel; Maria Roberta Cilio
Journal:  Lancet Neurol       Date:  2015-12-24       Impact factor: 44.182

Review 2.  International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂.

Authors:  R G Pertwee; A C Howlett; M E Abood; S P H Alexander; V Di Marzo; M R Elphick; P J Greasley; H S Hansen; G Kunos; K Mackie; R Mechoulam; R A Ross
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 3.  Anandamide and 2-arachidonoylglycerol: pharmacological properties, functional features, and emerging specificities of the two major endocannabinoids.

Authors:  Antonio Luchicchi; Marco Pistis
Journal:  Mol Neurobiol       Date:  2012-07-17       Impact factor: 5.590

4.  Cannabidiol interferes with the effects of delta 9 - tetrahydrocannabinol in man.

Authors:  I G Karniol; I Shirakawa; N Kasinski; A Pfeferman; E A Carlini
Journal:  Eur J Pharmacol       Date:  1974-09       Impact factor: 4.432

5.  The isolation and structure of delta-1-tetrahydrocannabinol and other neutral cannabinoids from hashish.

Authors:  Y Gaoni; R Mechoulam
Journal:  J Am Chem Soc       Date:  1971-01-13       Impact factor: 15.419

Review 6.  An Introduction to the Endogenous Cannabinoid System.

Authors:  Hui-Chen Lu; Ken Mackie
Journal:  Biol Psychiatry       Date:  2015-10-30       Impact factor: 13.382

Review 7.  CB(1) cannabinoid receptors and their associated proteins.

Authors:  Allyn C Howlett; Lawrence C Blume; George D Dalton
Journal:  Curr Med Chem       Date:  2010       Impact factor: 4.530

Review 8.  Molecular Targets of Cannabidiol in Neurological Disorders.

Authors:  Clementino Ibeas Bih; Tong Chen; Alistair V W Nunn; Michaël Bazelot; Mark Dallas; Benjamin J Whalley
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

Review 9.  An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies.

Authors:  Kerstin Iffland; Franjo Grotenhermen
Journal:  Cannabis Cannabinoid Res       Date:  2017-06-01
View more
  15 in total

Review 1.  All roads lead to inflammation: Is maternal immune activation a common culprit behind environmental factors impacting offspring neural control of breathing?

Authors:  Andrew O Knutson; Jyoti J Watters
Journal:  Respir Physiol Neurobiol       Date:  2019-12-23       Impact factor: 1.931

2.  Neuropharmacological Effects of the Main Phytocannabinoids: A Narrative Review.

Authors:  Rafael G Dos Santos; Jaime E C Hallak; José Alexandre S Crippa
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  Cannabis and the Developing Adolescent Brain.

Authors:  Adina S Fischer; Susan F Tapert; Dexter Lee Louie; Alan F Schatzberg; Manpreet K Singh
Journal:  Curr Treat Options Psychiatry       Date:  2020-04-18

4.  Ontogeny and programming of the fetal temporal cortical endocannabinoid system by moderate maternal nutrient reduction in baboons (Papio spp.).

Authors:  Kushal Gandhi; Vanessa Montoya-Uribe; Stacy Martinez; Samuel David; Bobby Jain; Grace Shim; Cun Li; Susan Jenkins; Peter Nathanielsz; Natalia Schlabritz-Loutsevitch
Journal:  Physiol Rep       Date:  2019-03

Review 5.  Cannabidiol as a potential treatment for psychosis.

Authors:  Cathy Davies; Sagnik Bhattacharyya
Journal:  Ther Adv Psychopharmacol       Date:  2019-11-08

6.  Effects of cannabinoids on the development of chick embryos in ovo.

Authors:  Sofia B Gustafsson; Stig O P Jacobsson
Journal:  Sci Rep       Date:  2019-09-17       Impact factor: 4.379

Review 7.  Medical Cannabis in Children.

Authors:  Adi Aran; Dalit Cayam-Rand
Journal:  Rambam Maimonides Med J       Date:  2020-01-30

8.  Efficacy and Tolerance of Synthetic Cannabidiol for Treatment of Drug Resistant Epilepsy.

Authors:  Kerstin A Klotz; Daniel Grob; Martin Hirsch; Birgitta Metternich; Andreas Schulze-Bonhage; Julia Jacobs
Journal:  Front Neurol       Date:  2019-12-10       Impact factor: 4.003

9.  Perinatal CBD or THC Exposure Results in Lasting Resistance to Fluoxetine in the Forced Swim Test: Reversal by Fatty Acid Amide Hydrolase Inhibition.

Authors:  Izaque de Sousa Maciel; Gabriel H D de Abreu; Claire T Johnson; Rida Bonday; Heather B Bradshaw; Ken Mackie; Hui-Chen Lu
Journal:  Cannabis Cannabinoid Res       Date:  2021-06-28

10.  Extension of the Theory of Planned Behavior (TPB) to Predict Patterns of Marijuana Use among Young Iranian Adults.

Authors:  Farzad Jalilian; Mehdi Mirzaei-Alavijeh; Mohammad Ahmadpanah; Shayan Mostafaei; Mehdi Kargar; Razieh Pirouzeh; Dena Sadeghi Bahmani; Serge Brand
Journal:  Int J Environ Res Public Health       Date:  2020-03-17       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.